Back to top
more

VIVUS, Inc. (VVUS)

(Delayed Data from NSDQ)

$3.73 USD

3.73
58,550

+0.03 (0.81%)

Updated May 3, 2019 04:13 PM ET

After-Market: $3.83 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Rigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA

by Zacks Equity Research

Rigel Pharmaceuticals, Inc. (RIGL) announced that the FDA has accepted its new drug application (NDA) seeking approval for its oral spleen tyrosine kinase inhibitor, fostamatinib for the treatment of patients with chronic and persistent immune thrombocytopenia

    Amgen's Xgeva Myeloma Label Expansion sBLA Accepted by FDA

    by Zacks Equity Research

    Amgen Inc. (AMGN) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) to expand the label of its key drug, Xgeva.

      Merrimack Completes Enrollment in Phase II Study for MM-141

      by Zacks Equity Research

      Merrimack Pharmaceuticals announced completion of enrollment in the ongoing phase II study, evaluatingMM-141 in combination with standard of care for treatment of patients with previously untreated metastatic pancreatic cancer.

        Seattle Genetics Halts Phase III Study on Leukemia Drug

        by Zacks Equity Research

        Seattle Genetics, Inc. (SGEN) announced that it will discontinue the phase III study, CASCADE o vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia (AML) patients.

          Fibrocell Science (FCSC) Looks Good: Stock Moves Up 13.9%

          by Zacks Equity Research

          Fibrocell Science, Inc. (FCSC) moved big last session, as its shares rose almost 14% on the day.

            Celgene Presents Interim Results from Cancer Drug Study

            by Zacks Equity Research

            Celgene Corporation (CELG) announced encouraging results from an interim analysis of a phase IIIb study, MAGNIFY, on Revlimid.

              Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205

              by Zacks Equity Research

              Bristol-Myers Squibb Company (BMY) announced an extended follow-up data on immuno-oncology drug Opdivo.

                GlaxoSmithKline's Benlysta Positive in Continuation Trial

                by Zacks Equity Research

                GlaxoSmithKline plc (GSK) announced positive results from a phase II continuation study evaluating the efficacy and safety of its marketed drug, Benlysta, in combination with standard of care for treatment systemic lupus erythematosus (SLE).

                  AveXis (AVXS) Surges: Stock Moves 5% Higher

                  by Zacks Equity Research

                  AveXis (AVXS) was a big mover last session, as the company saw its shares rise over 5% on the day.

                    Mallinckrodt Initiates Amyotrophic Lateral Sclerosis Study

                    by Zacks Equity Research

                    Mallinckrodt plc (MNK) announced that it has enrolled the first patient in its phase IIB study, PENNANT.

                      Omeros (OMER) Hits New 52-Week High on Positive FDA Decision

                      by Zacks Equity Research

                      Omeros Corporation (OMER) shares hit a new 52-week high of $22.80 on Thursday before eventually closing at $22.15.

                        Epizyme (EPZM) Jumps: Stock Rises 17.4%

                        by Zacks Equity Research

                        Epizyme (EPZM) was a big mover last session, as the company saw its shares rise over 17% on the day.

                          Selecta Biosciences (SELB) In Focus: Stock Moves 6.5% Higher

                          by Zacks Equity Research

                          Selecta Biosciences (SELB) moved big last session, as its shares jumped over 6% on the day.

                            NantKwest (NK) Looks Good: Stock Moves Up 8.5% in Session

                            by Zacks Equity Research

                            NantKwest, Inc. (NK) moved big last session, as its shares rose over 8% on the day.

                              Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial

                              by Zacks Equity Research

                              Celgene Corporation (CELG) announced results from the phase II trial, SLE-001 which evaluated lupus candidate, CC-220, at the Annual European Congress of Rheumatology (EULAR) 2017 in Madrid.

                                Novartis (NVS) Announced Positive Data on Psoriasis Cosentyx

                                by Zacks Equity Research

                                Novartis AG (NVS) announced positive data on arthritis drug Cosentyx from two phase III studies.

                                  Acceleron (XLRN) Kidney Cancer Candidate Fails in Phase II

                                  by Zacks Equity Research

                                  Acceleron Pharma Inc.'s (XLRN) announced disappointing results from a phase II study evaluating its pipeline candidate dalantercept in combination with Pfizer's (PFE) Inlyta (axitinib) for treatment of advanced renal cell carcinoma (RCC).

                                    Omeros (OMER) Lead Candidate Gets Breakthrough Designation

                                    by Zacks Equity Research

                                    Omeros Corporation (OMER) announced that the FDA granted breakthrough therapy designation to pipeline candidate OMS721.

                                      Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug

                                      by Zacks Equity Research

                                      Novo Nordisk (NVO) announced positive results from the post-hoc analysis of the cardiovascular outcomes study, LEADER on Victoza.

                                        Exelixis Initiates Cabozantinib-Tecentriq Combination Trial

                                        by Zacks Equity Research

                                        Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche's (RHHBY) Tecentriq.

                                          Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen

                                          by Zacks Equity Research

                                          Gilead Sciences, Inc. (GILD) announced that it has submitted a NDA to the FDA for an investigational HIV combination therapy regimen.

                                            Seres Therapeutics' Stock Up as SER-109 Moves to Phase III

                                            by Zacks Equity Research

                                            Shares of Seres Therapeutics, Inc. (MCRB) went up by more than 5% on Monday, after it announced that its lead pipeline candidate, SER-109, has moved into late-stage development for the treatment of multiply recurrent C. difficile infection.

                                              GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up

                                              by Zacks Equity Research

                                              GTx, Inc.'s (GTXI) shares have climbed almost 99% after the company announced positive data from a phase II study, evaluating enobosarm for treating postmenopausal women with stress urinary incontinence.

                                                Intercept (ICPT) Releases Data from Phase II Flint Trial

                                                by Zacks Equity Research

                                                Intercept Pharmaceuticals, Inc. (ICPT) announced a retrospective analysis of the phase II trial, FLINT, in patients who were diagnosed with nonalcoholic steatohepatitis (NASH) and type II diabetes.

                                                  Amgen's Multiple Myeloma Drug Receives NICE Recommendation

                                                  by Zacks Equity Research

                                                  Amgen Inc. (AMGN) announced that Kyprolis gained recommendation from National Institute for Health and Care Excellence (NICE) in combination with dexamethasone for the treatment of relapsed multiple myeloma.